US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics
Larimar Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bala Cynwyd, USA HQ
2016 Founded
82 Employees
Public company Type
LRMR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bala Cynwyd, USA
- Founded
- 2016
- Employees
- 82
- Programs
- 3
- Drugs
- 2
- Patents
- 5
Larimar Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Larimar Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Larimar Therapeutics in public FDA and regional records.